Kenvue Target of Unusually Large Options Trading (NYSE:KVUE)

Kenvue Inc. (NYSE:KVUE - Get Free Report) saw unusually large options trading on Monday. Stock investors bought 61,496 call options on the stock. This is an increase of 564% compared to the average volume of 9,267 call options.

Hedge Funds Weigh In On Kenvue

Several institutional investors have recently bought and sold shares of KVUE. Price T Rowe Associates Inc. MD grew its holdings in Kenvue by 3.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company's stock worth $5,249,665,000 after acquiring an additional 8,211,748 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Kenvue by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 218,543,705 shares of the company's stock valued at $4,665,908,000 after purchasing an additional 1,636,741 shares in the last quarter. State Street Corp raised its position in Kenvue by 16.8% in the 3rd quarter. State Street Corp now owns 127,213,940 shares of the company's stock worth $2,942,458,000 after purchasing an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Kenvue by 12.3% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after buying an additional 10,682,003 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Kenvue by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 46,068,931 shares of the company's stock valued at $980,989,000 after buying an additional 1,391,854 shares during the last quarter. Institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

KVUE has been the subject of several research reports. Evercore ISI assumed coverage on Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective for the company. Royal Bank of Canada reissued a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. UBS Group reduced their target price on shares of Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Friday, February 7th. Finally, Citigroup decreased their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $24.00.

Remove Ads

Kenvue Price Performance

Kenvue stock traded down $0.23 during mid-day trading on Thursday, hitting $23.65. 21,703,204 shares of the company were exchanged, compared to its average volume of 16,767,870. The company has a market capitalization of $45.19 billion, a PE ratio of 44.61, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. The business has a fifty day moving average of $22.50 and a 200 day moving average of $22.47. Kenvue has a 1-year low of $17.67 and a 1-year high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, sell-side analysts expect that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.47%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.